Action for Pulmonary Fibrosis (APF) and the U.K. Royal College of General Practitioners (RCGP) have created and launched a training module to help doctors provide better care for patients with pulmonary fibrosis (PF). The training will cover the signs and symptoms of PF, as well as where to…
The amount of bilirubin in the blood might predict the progression of idiopathic pulmonary fibrosis (IPF), according to a recent study. If validated in larger studies, bilirubin levels in the blood — or serum bilirubin — could offer a cheaper, simpler, and more convenient blood test than other…
From lighting landmarks in blue to showcasing patient stories, supporters are finding ways to mark Pulmonary Fibrosis Awareness Month, set aside each September to call attention to the lung condition and raise funds to fight it. The monthlong campaign is spearheaded each year by the Pulmonary Fibrosis Foundation…
A new 3D model of lung tissue allowed the scientists who developed it to identify aspects of pulmonary fibrosis (PF) not evident in the 2D models often used in research. This new model, developed by a research team at the University of Michigan, revealed potentially important aspects of fibrosis and…
Using Cymerus mesenchymal stem cells (MSCs) to treat idiopathic pulmonary fibrosis (IPF) resulted in dramatic reductions in IPF symptoms and significant improvements in lung functionality in an animal model of the disease, Cynata Therapeutics, the company developing this stem cell therapy, reported. These…
In recognition of September being Pulmonary Fibrosis Awareness Month, the Pulmonary Fibrosis Foundation (PFF) is working to raise awareness about the realities of this disease and how it affects people’s lives. The PFF is also conducting a social media campaign, “30 Facts in 30 Days,” to educate the public…
Procalcitonin, a precursor of the calcitonin hormone, may be used as a potential biomarker of lung cancer developing in people with idiopathic pulmonary fibrosis (IPF), a recent study suggests. Compared with patients with IPF alone, procalcitonin was significantly higher in IPF patients who also had lung…
An inhaled formulation of nintedanib — the active ingredient in Ofev — demonstrated enhanced antifibrotic effects after short-duration doses compared to oral formulations given at a higher dose in a rat model with induced idiopathic pulmonary…
Ofev (nintedanib) is safe and effective for adults with idiopathic pulmonary fibrosis (IPF) with poorer lung function, a small real-world analysis has found. Age and lung function predicted the therapy’s efficacy in this group of patients. …
Research investigating the role of immune cells in triggering lung and heart rejection following transplant will be supported by $10 million in grants from the National Institutes of Health (NIH). The grants, awarded to scientists at Washington University School of Medicine in St. Louis, will support research that aims…
Get regular updates to your inbox.
